SEVOFRANE Side Effects

6812939-8 | Atrioventricular Block Complete, Cardiovascular Insufficiency
on Jun 23, 2010 Female patient from JAPAN , weighting 27.78 lb, was diagnosed with induction and maintenance of anaesthesia and was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: atrioventricular block complete, cardiovascular insufficiency. Sevofrane dosage: 2%. During the same period patient was treated with NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), DIURETIC AGENTS (View Diuretic Agents Review and Diuretic Agents Label ), INOTROPIC AGENTS (View Inotropic Agents Review and Inotropic Agents Label ), VASODEPRESSORS (View Vasodepressors Review and Vasodepressors Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), EPINEPHRINE (View Epinephrine Review and Epinephrine Label ).

6801473-7 | Atrioventricular Block Complete, Cardiovascular Insufficiency
Patient was taking Sevofrane (View Usage). Patient had the following side effects: atrioventricular block complete, cardiovascular insufficiency on Jun 22, 2010 from JAPAN Additional patient health information: Female patient , weighting 27.78 lb, was diagnosed with induction and maintenance of anaesthesia and. Sevofrane dosage: 2%. During the same period patient was treated with NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), DIURETIC AGENTS (View Diuretic Agents Review and Diuretic Agents Label ), INOTROPIC AGENTS (View Inotropic Agents Review and Inotropic Agents Label ), VASODEPRESSORS (View Vasodepressors Review and Vasodepressors Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), EPINEPHRINE (View Epinephrine Review and Epinephrine Label ).

6690089-1 | Hyperthermia Malignant, Multi-organ Failure
Adverse event was reported on Apr 13, 2010 by a Male patient taking Sevofrane (View Usage) (Dosage: ) was diagnosed with anaesthesia and. Location: CHINA , 37 years of age, weighting 156.5 lb, After Sevofrane was administered, patient had the following side effects: hyperthermia malignant, multi-organ failure. During the same period patient was treated with FORANE LIQUID (View Forane Liquid Review and Forane Liquid Label ), MIDAZOLAM HCL (2 Mg Daily) (View Midazolam Hcl Review and Midazolam Hcl Label ), PROPOFOL (100 Mg Daily) (View Propofol Review and Propofol Label ), CISATRACURIUM BESYLATE (8 Mg Daily) (View Cisatracurium Besylate Review and Cisatracurium Besylate Label ), FENTANYL (0.2 Mg Daily) (View Fentanyl Review and Fentanyl Label ).

6669711-1 | Hyperthermia Malignant, Multi-organ Failure
on Apr 01, 2010 Male patient from CHINA , 37 years of age, weighting 156.5 lb, was diagnosed with anaesthesia and was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: hyperthermia malignant, multi-organ failure. Sevofrane dosage: . During the same period patient was treated with FORANE LIQUID (View Forane Liquid Review and Forane Liquid Label ), MIDAZOLAM HCL (2 Mg Daily) (View Midazolam Hcl Review and Midazolam Hcl Label ), PROPOFOL (100 Mg Daily) (View Propofol Review and Propofol Label ), CISATRACURIUM BESYLATE (8 Mg Daily) (View Cisatracurium Besylate Review and Cisatracurium Besylate Label ), FENTANYL (0.2 Mg Daily) (View Fentanyl Review and Fentanyl Label ).


6655308-6 | Hyperthermia Malignant, Multi-organ Failure
on Mar 19, 2010 Female patient from JAPAN , weighting 110.2 lb, was diagnosed with infection prophylaxis and was treated with Sevofrane (View Usage). Patient had the following side effects: hyperthermia malignant, multi-organ failure. Sevofrane dosage: 1-3% Total Administration 70 Ml. During the same period patient was treated with FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), CEFAZOLIN SODIUM (View Cefazolin Sodium Review and Cefazolin Sodium Label ), L ASPARTATE POTASSIUM (View L-aspartate Potassium Review and L-aspartate Potassium Label ), ADONA (View Adona Review and Adona Label ), ANCOMA (MONOSODIUM L GLUTAMATE MONOHYDRATE) (View Ancoma (monosodium L-glutamate Monohydrate) Review and Ancoma (monosodium L-glutamate Monohydrate) Label ), INOVAN (View Inovan Review and Inovan Label ), CALCICOL (View Calcicol Review and Calcicol Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ).

6606634-8 | Blood Pressure Decreased, Hypercapnia, Hyperthermia, Hyperthermia Malignant, Hypoxia, Multi-organ Failure, Renal Failure Acute, Tachycardia, Tachypnoea
Patient was taking Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: blood pressure decreased, hypercapnia, hyperthermia, hyperthermia malignant, hypoxia, multi-organ failure, renal failure acute, tachycardia, tachypnoea on Feb 16, 2010 from JAPAN Additional patient health information: Female patient , weighting 110.2 lb, was diagnosed with infection prophylaxis and. Sevofrane dosage: 1-3% Total Administration 70 Ml. During the same period patient was treated with FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), CEFAZOLIN SODIUM (View Cefazolin Sodium Review and Cefazolin Sodium Label ), L ASPARTATE POTASSIUM (View L-aspartate Potassium Review and L-aspartate Potassium Label ), ADONA (View Adona Review and Adona Label ), ANCOMA (MONOSODIUM L GLUTAMATE MONOHYDRATE) (View Ancoma (monosodium L-glutamate Monohydrate) Review and Ancoma (monosodium L-glutamate Monohydrate) Label ), INOVAN (View Inovan Review and Inovan Label ), CALCICOL (View Calcicol Review and Calcicol Label ), LIDOCAINE (View Lidocaine Review and Lidocaine Label ).

6555790-9 | Hepatic Necrosis, Liver Disorder
Adverse event was reported on Jan 18, 2010 by a Male patient taking Sevofrane (View Usage) (Dosage: ) . Location: JAPAN , 36 years of age, Patient experienced the following unwanted or unexpected effects: hepatic necrosis, liver disorder. Patient was hospitalized.

6554006-7 | Liver Disorder
on Jan 18, 2010 Male patient from JAPAN , weighting 158.7 lb, was diagnosed with anaesthesia, surgery (What is surgery?) and was treated with Sevofrane (View Usage). Patient had the following side effects: liver disorder. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), DIAZEPAM (View Diazepam Review and Diazepam Label ), CEFAZOLIN SODIUM (View Cefazolin Sodium Review and Cefazolin Sodium Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), ATROPINE SULFATE HYDRATE (View Atropine Sulfate Hydrate Review and Atropine Sulfate Hydrate Label ), NEOSTIGMINE (View Neostigmine Review and Neostigmine Label ), THIAMYLAL SODIUM (View Thiamylal Sodium Review and Thiamylal Sodium Label ).

6521930-0 | Liver Disorder
on Dec 22, 2009 Male patient from JAPAN , 37 years of age, was treated with Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: liver disorder. Sevofrane dosage: . Patient was hospitalized.

6521929-4 | Liver Disorder
Patient was taking Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: liver disorder on Dec 22, 2009 from JAPAN Additional patient health information: Male patient , weighting 158.7 lb, was diagnosed with anaesthesia and. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ).

6512453-3 | Hepatic Necrosis, Liver Disorder, Lymphocyte Stimulation Test Positive
Adverse event was reported on Dec 09, 2009 by a Male patient taking Sevofrane (View Usage) (Dosage: ) was diagnosed with anaesthesia and. Location: JAPAN , weighting 158.7 lb, Patient had the following side effects: hepatic necrosis, liver disorder, lymphocyte stimulation test positive. During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ).

6507411-9 | Status Epilepticus
on Dec 11, 2009 Female patient from JAPAN , weighting 105.8 lb, was diagnosed with maintenance of anaesthesia, epilepsy (What is epilepsy?), induction of anaesthesia, endotracheal intubation and was treated with Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: status epilepticus. Sevofrane dosage: 1.2 - 1.5%. During the same period patient was treated with PHENYTOIN (View Phenytoin Review and Phenytoin Label ), BEPOTASTINE BESILATE (View Bepotastine Besilate Review and Bepotastine Besilate Label ), PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), REMIFENTANIL (0.1 - 0.2 Mcg/kg/min) (View Remifentanil Review and Remifentanil Label ). Patient was hospitalized and became disabled.

6505280-4 | Liver Disorder
on Dec 08, 2009 Male patient from JAPAN , weighting 158.7 lb, was diagnosed with anaesthesia and was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: liver disorder. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ).

6467488-6 | Liver Disorder
Patient was taking Sevofrane (View Usage). Patient had the following side effects: liver disorder on Nov 25, 2009 from JAPAN Additional patient health information: Male patient , 37 years of age, . Sevofrane dosage: . Patient was hospitalized.

6467340-6 | Liver Disorder
Adverse event was reported on Nov 25, 2009 by a Male patient taking Sevofrane (View Usage) (Dosage: ) . Location: JAPAN , 70 years of age, After Sevofrane was administered, patient had the following side effects: liver disorder.

6447064-1 | Hyperthermia Malignant, Pain In Extremity, Rhabdomyolysis
on Nov 10, 2009 Male patient from JAPAN , weighting 167.6 lb, was diagnosed with maintenance of anaesthesia, extubation, induction of anaesthesia, procedural pain and was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: hyperthermia malignant, pain in extremity, rhabdomyolysis. Sevofrane dosage: 1.5-2.0%. During the same period patient was treated with ATROPINE (View Atropine Review and Atropine Label ), MIDAZOLAM HCL (View Midazolam Hcl Review and Midazolam Hcl Label ), THIOPENTAL SODIUM (View Thiopental Sodium Review and Thiopental Sodium Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), NITROUS OXIDE (33%-50%) (View Nitrous Oxide Review and Nitrous Oxide Label ), FLURBIPROFEN (View Flurbiprofen Review and Flurbiprofen Label ).

6443311-0 | Ventricular Extrasystoles, Ventricular Fibrillation, Ventricular Tachycardia
on Nov 09, 2009 Male patient from JAPAN , 54 years of age, was diagnosed with induction of anaesthesia, maintenance of anaesthesia and was treated with Sevofrane (View Usage). Patient had the following side effects: ventricular extrasystoles, ventricular fibrillation, ventricular tachycardia. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), REMIFENTANIL (View Remifentanil Review and Remifentanil Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ). Patient was hospitalized.

6432599-8 | Hypercapnia, Laryngospasm, Obstructive Airways Disorder, Respiratory Arrest, Respiratory Depression
Patient was taking Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: hypercapnia, laryngospasm, obstructive airways disorder, respiratory arrest, respiratory depression on Nov 02, 2009 from JAPAN Additional patient health information: Female patient , weighting 92.59 lb, was diagnosed with maintenance of anaesthesia, induction of anaesthesia, anaesthesia reversal and. Sevofrane dosage: . During the same period patient was treated with FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), THIOPENTAL SODIUM (View Thiopental Sodium Review and Thiopental Sodium Label ), DROPERIDOL (View Droperidol Review and Droperidol Label ), VECURONIUM BROMIDE (MUSCULAX) (View Vecuronium Bromide (musculax) Review and Vecuronium Bromide (musculax) Label ), FLURBIPROFEN AXETIL (ROPION) (View Flurbiprofen Axetil (ropion) Review and Flurbiprofen Axetil (ropion) Label ), ATROPINE SULFATE HYDRATE (ATROPINE SULFATE HYDRATE) (View Atropine Sulfate Hydrate (atropine Sulfate Hydrate) Review and Atropine Sulfate Hydrate (atropine Sulfate Hydrate) Label ), NEOSTIGMINE (VAGOSTIGMIN) (View Neostigmine (vagostigmin) Review and Neostigmine (vagostigmin) Label ).

6429313-9 | Cerebral Disorder
Adverse event was reported on Oct 30, 2009 by a Male patient taking Sevofrane (View Usage) (Dosage: ) was diagnosed with maintenance of anaesthesia, induction of anaesthesia, hypotonia, tachycardia and. Location: JAPAN , 55 years of age, weighting 147.7 lb, Patient experienced the following unwanted or unexpected effects: cerebral disorder. During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), REMIFENTANIL HYDROCHLORIDE (0.25 - 1.0 Microgram/kg/min) (View Remifentanil Hydrochloride Review and Remifentanil Hydrochloride Label ), LANDIOLOL HYDROCHLORIDE (View Landiolol Hydrochloride Review and Landiolol Hydrochloride Label ).

6423738-3 | Blood Pressure Decreased, Pneumothorax
on Oct 23, 2009 Male patient from JAPAN , 77 years of age, was diagnosed with blood pressure (What is blood pressure?) and was treated with Sevofrane (View Usage). Patient had the following side effects: blood pressure decreased, pneumothorax. Sevofrane dosage: . During the same period patient was treated with FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), NOREPINEPHRINE BITARTRATE (View Norepinephrine Bitartrate Review and Norepinephrine Bitartrate Label ).

6422450-4 | Tracheomalacia
on Oct 20, 2009 Female patient from JAPAN , weighting 22.05 lb, was treated with Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: tracheomalacia. Sevofrane dosage: . During the same period patient was treated with NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ).

6422436-X | Cerebral Disorder
Patient was taking Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral disorder on Oct 22, 2009 from JAPAN Additional patient health information: Male patient , 55 years of age, weighting 147.7 lb, was diagnosed with maintenance of anaesthesia, induction of anaesthesia, hypotonia, tachycardia and. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), REMIFENTANIL HYDROCHLORIDE (0.25 - 1.0 Microgram/kg/min) (View Remifentanil Hydrochloride Review and Remifentanil Hydrochloride Label ), LANDIOLOL HYDROCHLORIDE (View Landiolol Hydrochloride Review and Landiolol Hydrochloride Label ).

6412798-1 | Blood Pressure Decreased, Pneumothorax
Adverse event was reported on Oct 16, 2009 by a Male patient taking Sevofrane (View Usage) (Dosage: ) . Location: JAPAN , 77 years of age, Patient had the following side effects: blood pressure decreased, pneumothorax. During the same period patient was treated with FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ).

6409841-2 | Nervous System Disorder
on Oct 13, 2009 Male patient from JAPAN , 55 years of age, was diagnosed with maintenance of anaesthesia, induction of anaesthesia and was treated with Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: nervous system disorder. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ), OXYGEN (View Oxygen Review and Oxygen Label ), REMIFENTANIL (View Remifentanil Review and Remifentanil Label ).

6393962-7 | Tracheomalacia
on Oct 06, 2009 Female patient from JAPAN , weighting 22.05 lb, was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: tracheomalacia. Sevofrane dosage: . During the same period patient was treated with NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), FENTANYL 100 (View Fentanyl-100 Review and Fentanyl-100 Label ), ROCURONIUM BROMIDE (View Rocuronium Bromide Review and Rocuronium Bromide Label ).

6382413-4 | Hypercapnia, Laryngospasm, Obstructive Airways Disorder, Respiratory Arrest, Respiratory Depression
Patient was taking Sevofrane (View Usage). Patient had the following side effects: hypercapnia, laryngospasm, obstructive airways disorder, respiratory arrest, respiratory depression on Sep 24, 2009 from JAPAN Additional patient health information: Female patient , weighting 92.59 lb, was diagnosed with maintenance of anaesthesia, induction of anaesthesia, anaesthesia reversal and. Sevofrane dosage: . During the same period patient was treated with FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), NITROUS OXIDE (View Nitrous Oxide Review and Nitrous Oxide Label ), THIOPENTAL SODIUM (View Thiopental Sodium Review and Thiopental Sodium Label ), DROPERIDOL (View Droperidol Review and Droperidol Label ), VECURONIUM BROMIDE (MUSCULAX) (View Vecuronium Bromide (musculax) Review and Vecuronium Bromide (musculax) Label ), FLURBIPROFEN AXETIL (ROPION) (View Flurbiprofen Axetil (ropion) Review and Flurbiprofen Axetil (ropion) Label ), ATROPINE SULFATE HYDRATE (ATROPINE SULFATE HYDRATE) (View Atropine Sulfate Hydrate (atropine Sulfate Hydrate) Review and Atropine Sulfate Hydrate (atropine Sulfate Hydrate) Label ), NEOSTIGMINE (VAGOSTIGMIN) (View Neostigmine (vagostigmin) Review and Neostigmine (vagostigmin) Label ).

6099169-5 | Anaphylactic Shock
Adverse event was reported on Feb 25, 2009 by a Female patient taking Sevofrane (View Usage) (Dosage: ) was diagnosed with anaesthesia and. Location: JAPAN , 73 years of age, After Sevofrane was administered, patient had the following side effects: anaphylactic shock. During the same period patient was treated with CEFMETAZOLE (View Cefmetazole Review and Cefmetazole Label ), SALINHES (View Salinhes Review and Salinhes Label ), ISODINE (View Isodine Review and Isodine Label ).

6076035-2 | Atrioventricular Block Complete, Myocardial Ischaemia
on Feb 10, 2009 Female patient from JAPAN , weighting 119.0 lb, was diagnosed with induction of anaesthesia, endotracheal intubation, hypertension and was treated with Sevofrane (View Usage). Patient experienced the following unwanted or unexpected effects: atrioventricular block complete, myocardial ischaemia. Sevofrane dosage: 5%. During the same period patient was treated with ATROPINE SULFATE (View Atropine Sulfate Review and Atropine Sulfate Label ), PROPOFOL (View Propofol Review and Propofol Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ), DIAZEPAM (View Diazepam Review and Diazepam Label ), AMLODIN (View Amlodin Review and Amlodin Label ).

6063975-3 | Blood Creatine Phosphokinase Increased, Blood Pressure Decreased, Body Temperature Increased, Convulsion, Deep Vein Thrombosis, Depressed Level Of Consciousness, Heart Rate Increased
on Jan 27, 2009 Female patient from JAPAN , weighting 110.7 lb, was diagnosed with maintenance of anaesthesia, analgesia, sedation, tachycardia, blood pressure increased, pyrexia, hypotonia and was treated with Sevofrane (View Usage). Patient had the following side effects: blood creatine phosphokinase increased, blood pressure decreased, body temperature increased, convulsion, deep vein thrombosis (What is deep vein thrombosis?), depressed level of consciousness, heart rate increased. Sevofrane dosage: 0.7-4.3%. During the same period patient was treated with OPYSTAN (View Opystan Review and Opystan Label ), BREVIBLOC (View Brevibloc Review and Brevibloc Label ), PERDIPINE (View Perdipine Review and Perdipine Label ), ROPION (View Ropion Review and Ropion Label ), ESLAX (ROCURONIUM BROMIDE) (View Eslax (rocuronium Bromide) Review and Eslax (rocuronium Bromide) Label ). Patient was hospitalized.

5114290-3 | Arteriospasm Coronary, Atrioventricular Block Third Degree, Blood Pressure Decreased, Bradycardia, Electrocardiogram Qrs Complex Prolonged
Patient was taking Sevofrane (View Usage). After Sevofrane was administered, patient had the following side effects: arteriospasm coronary, atrioventricular block third degree, blood pressure decreased, bradycardia, electrocardiogram qrs complex prolonged on Sep 15, 2006 from JAPAN Additional patient health information: Female patient , 63 years of age, weighting 127.9 lb, was diagnosed with anaesthesia, induction of anaesthesia and. Sevofrane dosage: . During the same period patient was treated with PROPOFOL (View Propofol Review and Propofol Label ), NITROUS OXIDE W/ OXYGEN (View Nitrous Oxide W/ Oxygen Review and Nitrous Oxide W/ Oxygen Label ), FENTANYL (View Fentanyl Review and Fentanyl Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ).